UK MHRA Adapts Inspections Program To Account For Increase In Pharmacovigilance Outsourcing
As drug companies increasingly outsource their pharmacovigilance activities to third party organizations, the UK regulator has made changes to its inspections program so that all affected marketing authorization holders are kept abreast of any problems identified at contract service providers.
You may also be interested in...
The UK Medicines and Healthcare Products Regulatory Agency has launched a pilot to ascertain whether the introduction of a new standalone program, under which it would inspect pharmacovigilance service providers, could cut inspection costs incurred by drug companies that use these third-party organizations and also save agency resources.
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.